Pre-Workout on Exercise Performance and Cognition

NCT ID: NCT02255201

Last Updated: 2015-04-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-10-31

Study Completion Date

2015-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the effects of four different pre-workout beverages as compared to placebo on muscular strength and endurance, perceived energy and cognitive performance in healthy adult males.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Beverage A

Single dose, Pre-Workout Master Performance Blend Dose 1

Group Type ACTIVE_COMPARATOR

Master Performance Blend Dose 1

Intervention Type DIETARY_SUPPLEMENT

Caffeine content: 200 mg

Beverage B

Single dose, Pre-Workout Master Performance Blend Dose 2

Group Type ACTIVE_COMPARATOR

Master Performance Blend Dose 2

Intervention Type DIETARY_SUPPLEMENT

Caffeine content: 400 mg

Beverage C

Single dose, Pre-Workout Performance Energy Blend

Group Type ACTIVE_COMPARATOR

Performance Energy Blend

Intervention Type DIETARY_SUPPLEMENT

Caffeine content: 175 mg

Beverage D

Single dose, Pre-Workout Energy Blend

Group Type ACTIVE_COMPARATOR

Energy Blend

Intervention Type DIETARY_SUPPLEMENT

Caffeine content: 200 mg

Beverage E

Single dose, Pre-Workout Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

Caffeine content: 0 mg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Master Performance Blend Dose 1

Caffeine content: 200 mg

Intervention Type DIETARY_SUPPLEMENT

Master Performance Blend Dose 2

Caffeine content: 400 mg

Intervention Type DIETARY_SUPPLEMENT

Performance Energy Blend

Caffeine content: 175 mg

Intervention Type DIETARY_SUPPLEMENT

Energy Blend

Caffeine content: 200 mg

Intervention Type DIETARY_SUPPLEMENT

Placebo

Caffeine content: 0 mg

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Males, aged 18 to 40 years
2. Subject has a waist circumference ≤ 97 cm.
3. Subject is a non-smoker.
4. Subject is in good health and appropriate for exercise as determined by physical examination, medical history and ECG.
5. Subject is weight training for the 6 months prior to starting the trial.
6. Subject agrees to not use any new vitamins and/or minerals until after study completion and to not take any vitamins and/or minerals 24 hours prior to the test visits.
7. Subject agrees to not use any dietary or herbal supplements until after study completion. A 7-day washout is allowed for study inclusion.
8. Subject is willing and able to comply with the protocol including:

* Attending 5 visits each of which is approximately 4 hours long;
* Refraining from caffeine, over-the-counter medications and alcohol for the 24 hours prior to the test visits;
* Refraining from weight training for the 48 hours prior and refraining from any exercise other than weight training for 24 hours prior to the test visits;
* Refraining from taking any dietary or herbal supplements throughout the study.
9. Subject is able to understand and sign the informed consent to participate in the study.

Exclusion Criteria

1. Subject has any of the following medical conditions:

* active heart disease
* uncontrolled high blood pressure (≥ 140/90 mmHg)
* renal or hepatic impairment/disease
* Type I or II diabetes
* bipolar disorder
* pulmonary disease (including current asthma)
* Parkinson's disease
* Seizure disorder
* unstable thyroid disease
* immune disorder (such as HIV/AIDS)
* active psychiatric disorders (including anxiety disorders)
* bleeding disorders
* gastrointestinal ulcer disease
* any medical condition deemed exclusionary by the Principal Investigator (PI)
2. Subject has any orthopedic problem(s) or history of musculoskeletal injury(ies) which make(s) resistance weight training contraindicated.
3. Subject has a history of cancer (except localized skin cancer without metastases) within 5 years prior to screening.
4. No prescription or chronic medication use allowed without PI discretion.
5. Subject is currently taking and unwilling to refrain from taking any over-the-counter stimulant medications/supplements (see section 2.6.2); seven-day washout required for study inclusion.
6. Subject is currently taking and unwilling to refrain from taking any over-the-counter allergy or asthma medication containing pseudoephedrine or ephedrine (see section 2.6.2); seven-day washout required for study inclusion.
7. Subject has an allergy to milk and phenylalanine, or any of the ingredients in the test product (see section 3.2.1).
8. Subject reports sensitivity to caffeine and/or beta-alanine.
9. Subject reports being a regular caffeine consumer defined as consuming \> 600 mg of caffeine per day.
10. Subject exhibits evidence of hepatic or renal dysfunction as evidenced by ALT, AST, AP being ≥ two times the upper limit of normal or serum creatinine value ≥ 2.0 mg/dl or other clinically significant abnormal clinical laboratory value per PI discretion.
11. Subject has a clinically relevant abnormality as defined by the PI or interpreting physician with respect to the ECG.
12. Subject has a QTcB interval \> 450 msec.
13. Subject has a history of drug or alcohol abuse in the past 12 months.
14. Subject has any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the subject or the quality of the study data.
15. Subject has taken an investigational product within 30 days of the first exercise test visit (visit 2).
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Glanbia Performance Nutrition

UNKNOWN

Sponsor Role collaborator

Miami Research Associates

NETWORK

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Miami Research Associates

Miami, Florida, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GPN-2014

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

NEUROmuscular Training for Enhanced AGE Longevity
NCT06620666 ACTIVE_NOT_RECRUITING NA